Mucinex Line Extensions Underscore Adams’ Commitment To Building OTCs
This article was originally published in The Tan Sheet
Executive Summary
A major task facing Adams Respiratory Therapeutics' new VP-OTC Marketing & Business Development Robert Casale will be to plan a Fall 2004 launch of extensions to the firm's Mucinex expectorant brand
You may also be interested in...
Adams Pulls Off Trade For Mucinex Complement
Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line
Adams Pulls Off Trade For Mucinex Complement
Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line
Adams Pulls Off Trade For Mucinex Complement
Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line